ALZN

Alzamend Neuro, Inc. (ALZN) - Q2 2024 Filing Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended October 31, 2024. Alzamend Neuro, Inc. is a clinical-stage biopharmaceutical company developing two primary product candidates: AL001 (a lithium-based ionic cocrystal for Alzheimer's, bipolar disorder, MDD, and PTSD) and ALZN002 (an immunotherapy vaccine for Alzheimer's). The company has generated no product revenue to date and relies on equity and debt financing to fund operations.

Key Financial Metrics

Material Changes vs. Prior Period

• Expense Reduction: Total operating expenses decreased significantly by 53% in Q2 2024 ($1.36M) compared to Q2 2023 ($2.90M). This was driven primarily by an 84% decrease in Research and Development (R&D) expenses ($311k vs. $2.0M), attributed to lower professional and clinical trial fees.
• Financing Activity: The company raised substantial capital in the first half of 2024. Net cash provided by financing activities was $8.26 million for the six months ended October 31, 2024, compared to only $18k in the prior year period. This included proceeds from Series A and Series B Convertible Preferred Stock and an At-The-Market (ATM) offering.
• Liquidity Improvement: Cash balances increased from $376,048 at April 30, 2024, to $4,093,073 at October 31, 2024.
• Stock Structure: The company completed a 1-for-10 reverse stock split effective July 16, 2024. All share data in the filing reflects this adjustment.

Outlook, Risks, and Management Commentary

• Going Concern Warning: Management states there is substantial doubt about the company's ability to continue as a going concern for at least one year from the filing date without additional financing. Current cash is deemed insufficient to fund planned operations through that period.
• Capital Strategy: The company is actively raising funds through the sale of Series A and Series B Convertible Preferred Stock and an ATM offering (up to $6.5M authorized). Management believes current cash plus anticipated proceeds from these offerings will meet requirements for the next 12 months.
• Clinical Progress:
  • AL001: Partnered with Massachusetts General Hospital for five clinical trials. Recent nonclinical data showed AL001 achieved higher brain lithium concentrations with lower plasma levels compared to lithium carbonate, suggesting a better safety profile.
  • ALZN002: The company terminated its contract with CRO Biorasi, LLC, in February 2024 and is seeking a replacement to continue Phase I/IIA trials.
• Internal Controls: The company disclosed that its internal control over financial reporting was not effective due to material weaknesses, including insufficient accounting resources and ineffective user access controls. Remediation plans are underway.
• Dividends: Series A Preferred Stock accrues dividends at 15% annually. Dividends of $53,651 were recorded for the three and six months ended October 31, 2024.

Investor Verification Checklist

• Runway Validation: Verify the timeline and certainty of closing the remaining tranches of the Series A Preferred Stock financing with Orchid Finance, LLC, which is contingent on milestones and stock price floors.
• CRO Replacement: Confirm the status of securing a new Contract Research Organization (CRO) for the ALZN002 clinical trial following the termination of the Biorasi contract.
• Internal Control Remediation: Monitor progress on fixing the material weaknesses in internal controls, specifically regarding accounting staffing and IT access controls, to ensure future financial reporting reliability.
• Dilution Impact: Assess the potential dilution from the conversion of outstanding Series A and Series B Preferred Stock and the exercise of warrants (873,450 warrants outstanding).
• License Milestones: Review upcoming royalty and milestone payment obligations to the University of South Florida Research Foundation, including a $1.25M payment due in March 2025 upon the first patient treated in a Phase III trial for AL001.